BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S, Trifirò G. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 2020;15:141. [PMID: 32503598 DOI: 10.1186/s13023-020-01430-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Mitelman O, Abdel-Hamid HZ, Byrne BJ, Connolly AM, Heydemann P, Proud C, Shieh PB, Wagner KR, Dugar A, Santra S, Signorovitch J, Goemans N, McDonald CM, Mercuri E, Mendell JR; investigators from the LNMRC Natural History study., investigators from the CINRG Duchenne National History Study., investigators from The DMD Italian Group. A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. J Neuromuscul Dis 2021. [PMID: 34420980 DOI: 10.3233/JND-210665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Zhang J, Chou OH, Tse YL, Ng KM, Tse HF. Application of Patient-Specific iPSCs for Modelling and Treatment of X-Linked Cardiomyopathies. Int J Mol Sci 2021;22:8132. [PMID: 34360897 DOI: 10.3390/ijms22158132] [Reference Citation Analysis]
3 Huang K, Bi FF, Yang H. A Systematic Review and Meta-Analysis of the Prevalence of Congenital Myopathy. Front Neurol 2021;12:761636. [PMID: 34795634 DOI: 10.3389/fneur.2021.761636] [Reference Citation Analysis]
4 Fukumoto Y, Miyama T. Alleviation of masticatory disturbance with an occlusal splint in a Duchenne muscular dystrophy patient. Spec Care Dentist 2021;41:572-8. [PMID: 33826161 DOI: 10.1111/scd.12594] [Reference Citation Analysis]
5 Xia Q, Huang X, Huang J, Zheng Y, March ME, Li J, Wei Y. The Role of Autophagy in Skeletal Muscle Diseases. Front Physiol 2021;12:638983. [PMID: 33841177 DOI: 10.3389/fphys.2021.638983] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Llamosas-Falcón L, Sánchez-Díaz G, Gallego E, Villaverde-Hueso A, Arias-Merino G, Posada de la Paz M, Alonso-Ferreira V. A population-based study of mortality due to muscular dystrophies across a 36-year period in Spain. Sci Rep 2022;12:3750. [PMID: 35260676 DOI: 10.1038/s41598-022-07814-z] [Reference Citation Analysis]
7 Nagabushana D, Polavarapu K, Bardhan M, Arunachal G, Gunasekaran S, Preethish-Kumar V, Anjanappa RM, Thomas P, Sadasivan A, Vengalil S, Nashi S, Chawla T, Warrier M, Keerthipriya M, Raju S, Mohan D, Nalini A. Comparison of The Carrier Frequency of Pathogenic Variants of DMD Gene in an Indian Cohort. J Neuromuscul Dis 2021;8:525-35. [PMID: 33843695 DOI: 10.3233/JND-210658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Giovarelli M, Zecchini S, Catarinella G, Moscheni C, Sartori P, Barbieri C, Roux-Biejat P, Napoli A, Vantaggiato C, Cervia D, Perrotta C, Clementi E, Latella L, De Palma C. Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy. Pharmacol Res 2021;170:105751. [PMID: 34197911 DOI: 10.1016/j.phrs.2021.105751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lim KRQ, Woo S, Melo D, Huang Y, Dzierlega K, Shah MNA, Aslesh T, Roshmi RR, Echigoya Y, Maruyama R, Moulton HM, Yokota T. Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2022;119:e2112546119. [PMID: 35193974 DOI: 10.1073/pnas.2112546119] [Reference Citation Analysis]
10 Yao S, Chen Z, Yu Y, Zhang N, Jiang H, Zhang G, Zhang Z, Zhang B. Current Pharmacological Strategies for Duchenne Muscular Dystrophy. Front Cell Dev Biol 2021;9:689533. [PMID: 34490244 DOI: 10.3389/fcell.2021.689533] [Reference Citation Analysis]
11 Nair KS, Lott DJ, Forbes SC, Barnard AM, Willcocks RJ, Senesac CR, Daniels MJ, Harrington AT, Tennekoon GI, Zilke K, Finanger EL, Finkel RS, Rooney WD, Walter GA, Vandenborne K. Step Activity Monitoring in Boys with Duchenne Muscular Dystrophy and its Correlation with Magnetic Resonance Measures and Functional Performance. J Neuromuscul Dis 2022. [PMID: 35466946 DOI: 10.3233/JND-210746] [Reference Citation Analysis]
12 Ghori FF, Wahid M. Induced pluripotent stem cells from urine of Duchenne muscular dystrophy patients. Pediatr Int 2021;63:1038-47. [PMID: 33599058 DOI: 10.1111/ped.14655] [Reference Citation Analysis]
13 Happi Mbakam C, Lamothe G, Tremblay JP. Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy. Front Med (Lausanne) 2022;9:859930. [PMID: 35419381 DOI: 10.3389/fmed.2022.859930] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Starosta A, Konieczny P. Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy. Cell Mol Life Sci 2021;78:4867-91. [PMID: 33825942 DOI: 10.1007/s00018-021-03821-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Williams K, Davidson I, Rance M, Buesch K, Acaster S. A qualitative study on the impact of caring for an ambulatory individual with nonsense mutation Duchenne muscular dystrophy. J Patient Rep Outcomes 2021;5:71. [PMID: 34374872 DOI: 10.1186/s41687-021-00344-8] [Reference Citation Analysis]
16 Lim KRQ, Nguyen Q, Yokota T. Genotype-Phenotype Correlations in Duchenne and Becker Muscular Dystrophy Patients from the Canadian Neuromuscular Disease Registry. J Pers Med 2020;10:E241. [PMID: 33238405 DOI: 10.3390/jpm10040241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Stefano ME, Ferretti V, Mozzetta C. Synaptic alterations as a neurodevelopmental trait of Duchenne muscular dystrophy. Neurobiol Dis 2022;:105718. [PMID: 35390481 DOI: 10.1016/j.nbd.2022.105718] [Reference Citation Analysis]
18 Labisa P, Andreozzi V, Mota M, Monteiro S, Alves R, Almeida J, Vandewalle B, Felix J, Buesch K, Canhão H, Beitia Ortiz de Zarate I. Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study. Pharmacoecon Open 2021. [PMID: 34604937 DOI: 10.1007/s41669-021-00303-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Szabo SM, Audhya IF, Feeny D, Neumann P, Malone DC, Gooch KL. Societal perspectives on disease and treatment attributes characterizing rare diseases: a qualitative study from the United States. J Patient Rep Outcomes 2022;6:9. [PMID: 35072826 DOI: 10.1186/s41687-022-00413-6] [Reference Citation Analysis]
20 Wahlgren L, Kroksmark AK, Tulinius M, Sofou K. One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure. Eur J Epidemiol 2021. [PMID: 34802091 DOI: 10.1007/s10654-021-00819-4] [Reference Citation Analysis]
21 Mantuano P, Boccanegra B, Conte E, De Bellis M, Cirmi S, Sanarica F, Cappellari O, Arduino I, Cutrignelli A, Lopedota AA, Mele A, Denora N, De Luca A. β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation. Biomolecules 2021;11:1742. [PMID: 34827740 DOI: 10.3390/biom11111742] [Reference Citation Analysis]
22 Ohlendieck K, Swandulla D. Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy. Pflugers Arch 2021;473:1813-39. [PMID: 34553265 DOI: 10.1007/s00424-021-02623-1] [Reference Citation Analysis]
23 Wagner KR, Kuntz NL, Koenig E, East L, Upadhyay S, Han B, Shieh PB. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve 2021;64:285-92. [PMID: 34105177 DOI: 10.1002/mus.27347] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 Szabo SM, Audhya IF, Rogula B, Feeny D, Gooch KL. Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI). Health Qual Life Outcomes 2022;20:93. [PMID: 35690783 DOI: 10.1186/s12955-022-02001-0] [Reference Citation Analysis]
25 Megarbane A, Bizzari S, Deepthi A, Sabbagh S, Mansour H, Chouery E, Hmaimess G, Jabbour R, Mehawej C, Alame S, Hani A, Hasbini D, Ghanem I, Koussa S, Al-Ali MT, Obeid M, Talea DB, Lefranc G, Levy N, Leturcq F, El Hayek S, Delague V, Urtizberea A. A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort. J Neuromuscul Dis 2021. [PMID: 34602496 DOI: 10.3233/JND-210652] [Reference Citation Analysis]
26 de Freitas Nakata KC, da Silva Pereira PP, Salgado Riveros B. Creatine kinase test diagnostic accuracy in neonatal screening for Duchenne Muscular Dystrophy: A systematic review. Clin Biochem 2021;98:1-9. [PMID: 34626608 DOI: 10.1016/j.clinbiochem.2021.09.010] [Reference Citation Analysis]
27 Liao Q, Zhang Y, He J, Huang K. Global prevalence of myotonic dystrophy: an updated systematic review and meta-analysis. Neuroepidemiology 2022. [PMID: 35483324 DOI: 10.1159/000524734] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Migliore B, Zhou L, Duparc M, Robles V, Rehder C, Peay H, Kucera K. Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy. IJNS 2022;8:12. [DOI: 10.3390/ijns8010012] [Reference Citation Analysis]
29 Lace B, Micule I, Kenina V, Setlere S, Strautmanis J, Kazaine I, Taurina G, Murmane D, Grinfelde I, Kornejeva L, Krumina Z, Sterna O, Radovica-spalvina I, Vasiljeva I, Gailite L, Stavusis J, Livcane D, Kidere D, Malniece I, Inashkina I. Overview of Neuromuscular Disorder Molecular Diagnostic Experience for the Population of Latvia. Neurol Genet 2022;8:e685. [DOI: 10.1212/nxg.0000000000000685] [Reference Citation Analysis]
30 Soblechero-Martín P, López-Martínez A, de la Puente-Ovejero L, Vallejo-Illarramendi A, Arechavala-Gomeza V. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. Neuropathol Appl Neurobiol 2021. [PMID: 33999469 DOI: 10.1111/nan.12735] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Eser G, Topaloğlu H. Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy. Genes 2022;13:1241. [DOI: 10.3390/genes13071241] [Reference Citation Analysis]
32 Carey IM, Banchoff E, Nirmalananthan N, Harris T, DeWilde S, Chaudhry UAR, Cook DG. Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: A retrospective study using primary care data. PLoS One 2021;16:e0261983. [PMID: 34972157 DOI: 10.1371/journal.pone.0261983] [Reference Citation Analysis]
33 Kong W, Wu S, Zhang J, Lu C, Ding Y, Meng Y. Global epidemiology of mucopolysaccharidosis type III (Sanfilippo syndrome): an updated systematic review and meta-analysis. J Pediatr Endocrinol Metab 2021. [PMID: 34271605 DOI: 10.1515/jpem-2020-0742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Carlton J, Powell PA; Project HERCULES Carer Group. Measuring carer quality of life in Duchenne muscular dystrophy: a systematic review of the reliability and validity of self-report instruments using COSMIN. Health Qual Life Outcomes 2022;20. [DOI: 10.1186/s12955-022-01964-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Speed C, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Griggs RC, Straub V, van Ruiten H, Childs AM, Ciafaloni E, Shieh PB, Spinty S, Maggi L, Baranello G, Butterfield RJ, Horrocks IA, Roper H, Alhaswani Z, Flanigan KM, Kuntz NL, Manzur A, Darras BT, Kang PB, Morrison L, Krzesniak-Swinarska M, Mah JK, Mongini TE, Ricci F, von der Hagen M, Finkel RS, O'Reardon K, Wicklund M, Kumar A, McDonald CM, Han JJ, Joyce N, Henricson EK, Schara-Schmidt U, Gangfuss A, Wilichowski E, Barohn RJ, Statland JM, Campbell C, Vita G, Vita GL, Howard JF Jr, Hughes I, McMillan HJ, Pegoraro E, Bello L, Burnette WB, Thangarajh M, Chang T; FOR-DMD Investigators of the Muscle Study Group. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial. JAMA 2022. [PMID: 35381069 DOI: 10.1001/jama.2022.4315] [Reference Citation Analysis]
36 Fornander F, Solheim TÅ, Eisum AV, Poulsen NS, Andersen AG, Dahlqvist JR, Dunø M, Vissing J. Quantitative Muscle MRI and Clinical Findings in Women With Pathogenic Dystrophin Gene Variants. Front Neurol 2021;12:707837. [PMID: 34539555 DOI: 10.3389/fneur.2021.707837] [Reference Citation Analysis]
37 Namestnikova DD, Cherkashova EA, Sukhinich KK, Gubskiy IL, Leonov GE, Gubsky LV, Majouga AG, Yarygin KN. Combined Cell Therapy in the Treatment of Neurological Disorders. Biomedicines 2020;8:E613. [PMID: 33333803 DOI: 10.3390/biomedicines8120613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 Minai L, Yelin D. Plasmonic fusion between fibroblasts and skeletal muscle cells for skeletal muscle regeneration. Biomed Opt Express 2022;13:608. [DOI: 10.1364/boe.445290] [Reference Citation Analysis]
39 Palacios-espinosa X, Mateus H, Dávalos M, Gracia J, Bastidas-bilbao H. The experience of Colombian boys and young men living with Duchenne muscular dystrophy. Psicol USP 2021;32:e190171. [DOI: 10.1590/0103-6564e190171] [Reference Citation Analysis]
40 Barthélémy I, Calmels N, Weiss RB, Tiret L, Vulin A, Wein N, Peccate C, Drougard C, Beroud C, Deburgrave N, Thibaud JL, Escriou C, Punzón I, Garcia L, Kaplan JC, Flanigan KM, Leturcq F, Blot S. X-linked muscular dystrophy in a Labrador Retriever strain: phenotypic and molecular characterisation. Skelet Muscle 2020;10:23. [PMID: 32767978 DOI: 10.1186/s13395-020-00239-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
41 Zambon AA, Ayyar Gupta V, Ridout D, Manzur A, Baranello G, Trucco F, Muntoni F, Tirupath S, Douglas M, Mcfetridge J, Parasuraman D, Alhaswani Z, Mcmurchie H, Rabb R, Majumdar A, Vijayakumar K, Amin S, Mason F, Frimpong‐ansah C, Gibbon F, Parson B, Naismith K, Burslem J, Baxter A, Eadie C, Horrocks I, Di Marco M, Childs A, Pallant L, Spinty S, Shillington A, Gregson S, Cheshman L, Wraige E, Gowda V, Jungbluth H, Sheehan J, Hughes I, Warner S, Straub V, Guglieri M, Mayhew A, Chow G, Williamson S, Willis T, Kulshrestha R, Emery N, Ramdas S, Ramjattan H, de Goede C, Selley A, Ong M, White K, Illingworth M, Geary M, Palmer J, White C, Greenfield K, Hewawitharana G, Julien Y, Stephens E, Tewnion J, Ambegaonkar G, Krishnakumar D, Taylor J, Ward C, Willis T, Wright E, Rylance C; The UK Northstar Clinical Network. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Develop Med Child Neuro. [DOI: 10.1111/dmcn.15176] [Reference Citation Analysis]
42 Audic F, Catillon P, Berbis J, Paermentier L, Gizard F, Chabrol B. Use of a book to disclose a diagnosis of Duchenne muscular dystrophy to a young child: A pilot study. Arch Pediatr 2021:S0929-693X(21)00208-6. [PMID: 34876333 DOI: 10.1016/j.arcped.2021.10.008] [Reference Citation Analysis]
43 Servais L, Mercuri E, Straub V, Guglieri M, Seferian AM, Scoto M, Leone D, Koenig E, Khan N, Dugar A, Wang X, Han B, Wang D, Muntoni F; SKIP-NMD Study Group. Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Trial. Nucleic Acid Ther 2021. [PMID: 34788571 DOI: 10.1089/nat.2021.0043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
44 Lilien C, Reyngoudt H, Seferian AM, Gidaro T, Annoussamy M, Chê V, Decostre V, Ledoux I, Le Louër J, Guemas E, Muntoni F, Hogrel JY, Carlier PG, Servais L; and the PreU7 Study Group. Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy. Ann Clin Transl Neurol 2021;8:1938-50. [PMID: 34453498 DOI: 10.1002/acn3.51417] [Reference Citation Analysis]
45 Frinchi M, Morici G, Mudó G, Bonsignore MR, Di Liberto V. Beneficial Role of Exercise in the Modulation of mdx Muscle Plastic Remodeling and Oxidative Stress. Antioxidants (Basel) 2021;10:558. [PMID: 33916762 DOI: 10.3390/antiox10040558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Merckx C, De Paepe B. The Role of Taurine in Skeletal Muscle Functioning and Its Potential as a Supportive Treatment for Duchenne Muscular Dystrophy. Metabolites 2022;12:193. [DOI: 10.3390/metabo12020193] [Reference Citation Analysis]
47 Florczyk-Soluch U, Polak K, Dulak J. The multifaceted view of heart problem in Duchenne muscular dystrophy. Cell Mol Life Sci 2021;78:5447-68. [PMID: 34091693 DOI: 10.1007/s00018-021-03862-2] [Reference Citation Analysis]
48 Happi Mbakam C, Lamothe G, Tremblay G, Tremblay JP. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy. Neurotherapeutics 2022. [PMID: 35165856 DOI: 10.1007/s13311-022-01197-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Wang M, Li F, Zhang J, Lu C, Kong W. Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis. J Pediatr Hematol Oncol 2022. [PMID: 35867706 DOI: 10.1097/MPH.0000000000002506] [Reference Citation Analysis]
50 Imamoglu S, Kenis-coskun O, Deveci M, Ozturk G, Karadag-saygi E. Validity and Reliability of Quick Motor Function Test in Ambulatory Duchenne Muscular Dystrophy Patients. Journal of Pediatric Neurology. [DOI: 10.1055/s-0042-1743434] [Reference Citation Analysis]
51 Zabłocka B, Górecki DC, Zabłocki K. Disrupted Calcium Homeostasis in Duchenne Muscular Dystrophy: A Common Mechanism behind Diverse Consequences. Int J Mol Sci 2021;22:11040. [PMID: 34681707 DOI: 10.3390/ijms222011040] [Reference Citation Analysis]
52 Singh S, Singh T, Kunja C, Dhoat NS, Dhania NK. Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy. Eur J Pharmacol 2021;912:174568. [PMID: 34656607 DOI: 10.1016/j.ejphar.2021.174568] [Reference Citation Analysis]
53 Niu X, Menhart N. Structural Perturbations of Exon-Skipping Edits within the Dystrophin D20:24 Region. Biochemistry 2021;60:765-79. [PMID: 33656846 DOI: 10.1021/acs.biochem.0c00827] [Reference Citation Analysis]
54 Shastry A, Aravind S, Sunil M, Ramesh K, Ashley B, T N, Ramprasad VL, Gupta R, Seshagiri S, Nongthomba U, Phalke S. Matrilineal analysis of mutations in the DMD gene in a multigenerational South Indian cohort using DMD gene panel sequencing. Mol Genet Genomic Med 2021;9:e1633. [PMID: 33960727 DOI: 10.1002/mgg3.1633] [Reference Citation Analysis]
55 McDonald CM, Shieh PB, Abdel-Hamid HZ, Connolly AM, Ciafaloni E, Wagner KR, Goemans N, Mercuri E, Khan N, Koenig E, Malhotra J, Zhang W, Han B, Mendell JR; the Italian DMD Telethon Registry Study Group, Leuven NMRC Registry Investigators, CINRG Duchenne Natural History Investigators, and PROMOVI Trial Clinical Investigators. Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. J Neuromuscul Dis 2021. [PMID: 34120909 DOI: 10.3233/JND-210643] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Fralish Z, Lotz EM, Chavez T, Khodabukus A, Bursac N. Neuromuscular Development and Disease: Learning From in vitro and in vivo Models. Front Cell Dev Biol 2021;9:764732. [PMID: 34778273 DOI: 10.3389/fcell.2021.764732] [Reference Citation Analysis]
57 Wilton-clark H, Yokota T. Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot. Genes 2022;13:257. [DOI: 10.3390/genes13020257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Merckx C, Cosemans G, Zschüntzsch J, Raedt R, Schmidt J, De Paepe B, De Bleecker JL. Description of Osmolyte Pathways in Maturing Mdx Mice Reveals Altered Levels of Taurine and Sodium/Myo-Inositol Co-Transporters. Int J Mol Sci 2022;23:3251. [PMID: 35328671 DOI: 10.3390/ijms23063251] [Reference Citation Analysis]